McDonald, Mark W.Plankenhorn, David A.McMullen, Kevin P.Henderson, Mark A.Dropcho, Edward J.Shah, Mitesh V.Cohen-Gadol, Aaron A.2016-02-122016-02-122015-05McDonald, M. W., Plankenhorn, D. A., McMullen, K. P., Henderson, M. A., Dropcho, E. J., Shah, M. V., & Cohen-Gadol, A. A. (2015). Proton therapy for atypical meningiomas. Journal of neuro-oncology, 123(1), 123-128.https://hdl.handle.net/1805/8305We report clinical outcomes of proton therapy in patients with World Health Organization grade 2 (atypical) meningiomas. Between 2005 and 2013, 22 patients with atypical meningiomas were treated to a median dose of 63 Gy (RBE) using proton therapy, as an adjuvant therapy after surgery (n = 12) or for recurrence or progression of residual tumor (n = 10). Six patients had presumed radiation-induced meningiomas, but none had received prior radiotherapy for their meningioma. The median follow-up time after radiation was 39 months (range 7–104) and all patients remain alive at last follow-up. The 5-year estimate of local control was 71.1 % (95 % CI 49.3–92.9 %). The 5-year estimate of local control was 87.5 % following a radiation dose >60 Gy (RBE), compared to 50.0 % for ≤60 Gy (RBE) (p = 0.038). The 5-year estimate of neuraxis dissemination was 5 % (95 % CI 0–14.6 %) and 6.2 % (95 % CI 0–18.2 %) for metastases outside of the central nervous system. Radiation necrosis was observed in one patient with a history of prior cranial irradiation. Fractionated proton therapy was associated with favorable tumor control rates for grade 2 meningiomas. Prospective studies are needed to define the optimal radiation dose for high-grade meningiomas.en-USPublisher Policymeningiomaradiationproton therapyArticle